Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 1

Interventions

Specimen Handling 113Magnetic Resonance Spectroscopy 78Biopsy 78pembrolizumab 61Cyclophosphamide 52fludarabine 43Carboplatin 26Nivolumab 24Cetuximab 24Cisplatin 23venetoclax 22Radiotherapy 21Bevacizumab 21atezolizumab 18X-Rays 18fludarabine phosphate 17Radiation 17Ipilimumab 17Fluorouracil 17Gemcitabine 16Paclitaxel 15Leucovorin 15Cytarabine 15Temozolomide 14Pemetrexed 14Irinotecan 14durvalumab 13Oxaliplatin 13Azacitidine 13Prednisone 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Antineoplastic Agents × 30 days × Clear all
NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡